MAP2K7 and cancer: Not only that Erks are obvious targets for anti-cancer therapy because they are the downstream components of the RTK-Ras-Raf-MEK pathway, in the majority of cases of tumors resistant to EGFR, B-Raf and MEK inhibitors, re-activation of Erk is observed [84].